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ABSTRACT
Background: The mortality rate due to Acinetobacter baumannii nosocomial meningitis (ANM) is 
high. Objective: The aim of this study was to evaluate the factors that have inﬂ uence over the out-
comes in ANM patients. Methods: A retrospective analysis of 22 cases of ANM was conducted in 
a hospital with high incidence of multidrug resistance. Results: The mean age of patients was 43 
years (21 to 91) and 54.5% were male. All ANM cases occurred within 60 days of admission and 
the mean duration of illness was of 18.2 days. All cases were associated with previous neurosurgical 
procedures: elective surgery (27.2%), external shunt (54.4%) and emergency surgery due to trauma 
(18.1%). Imipenem resistance was observed in 40.9% of cases, but ampicillin/sulbactam resistance 
was lower (27.2%). The mortality rate of ANM patients was of 72.7%. The only risk factor associ-
ated with mortality was inappropriate therapy within fi ve days after CSF collection. All patients who 
survived the meningitis episode had received appropriate therapy, in contrast to only 69.2% of those 
who did not survive (OR = 5.15; IC = 0.45-54.01). Conclusions: The high mortality rate observed 
in our study suggests the need for aggressive empirical treatment with addition of drugs, including 
intrathecal therapy, where multi-resistant A. baumannii is endemic.
Keywords: Acinetobacter; meningitis; Acinetobacter baumannii; neurosurgery; imipenem; ampicil-
lin/sulbactam.
[Braz J Infect Dis 2010;14(5):437-440]©Elsevier Editora Ltda.
INTRODUCTION
Acinetobacter meningitis is a rare complication 
following neurosurgical procedures. Currently, 
Acinetobacter is the second most common agent 
of nosocomial meningitis in some hospitals.1 
The mortality rate is high and those who out-
live the infectious episode usually have severe 
neurological defi cits.2 The estimated 15% mor-
tality rate of nosocomial meningitis3 increases 
to 40% if caused by Acinetobacter.4 In develop-
ing countries, it can reach up to 70%.5
There have been no randomized controlled 
studies conducted to evaluate different treat-
ments for Acinetobacter meningitis. The cur-
rent treatment regimen is based on case reports 
and pharmacological data. 
Intrathecal therapy remains controversial 
due to divergent outcomes. The aim of this 
study was to evaluate the risk factors associ-
ated with treatment failure of nosocomial 
Acinetobacter meningitis in a cohort from a 
Brazilian hospital.
METHODS
The hospital records of 22 patients diagnosed 
with nosocomial Acinetobacter meningitis ad-
mitted from January 2006 to January 2009 were 
retrospectively reviewed. Inclusion criteria were: 
(i) clinical evidence of central nervous system 
infection, (ii) isolation of A. baumannii from 
cerebrospinal ﬂ uid, and (iii) acquisition of the 
infection more than 72 hours after hospital ad-
mission. Central nervous system infection was 
defi ned as increased white cell count (> 50% 
polymorphonuclear leucocytes), increased pro-
tein and/or decreased glucose (< 15 g/dL) in 
cerebrospinal ﬂ uid. A. baumannii identifi cation 
without cerebrospinal ﬂ uid alterations was con-
sidered contamination/colonization.1
Variables abstracted from the patient 
record, summarized in Table 1 and 2, were: 
gender, age, cerebrospinal ﬂ uid (number of 
leukocytes/mm3, glucose, and protein levels), 
history of trauma, presence of external shunt 
at the time of meningitis diagnosis, days of 
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admission before infection and total length of hospital 
stay, elective surgery, previous use of antibiotics, suscep-
tibility tests for Acinetobacter, antibiotic therapy (intra-
venous and intrathecal) used, and patient outcome. Aci-
netobacter baumannii was identified using biochemical 
methods. Antibiotic susceptibility was assayed by diffu-
sion disc according to CLSI.6
Appropriate therapy was defined as administration of 
one or more active agents against A. baumannii in ad-
equate doses and routes of administration.
Patient outcome was deemed successful if the patient 
had been discharged from hospital without re-admission 
within the following three months. All other outcomes 
were considered failure.
Statistical analyses were performed using the SPSS 
software (version 11; Chicago, IL, USA). Distribution of 
variables in the surviving and non-surviving groups was 
assessed by χ2 test or Fishers exact test for categorical vari-
ables, and by the Mann–Whitney test for continuous vari-
ables. Variables significantly associated with mortality in 
univariate analysis will be included in a binary multivari-
ate logistic regression model.
 
Table 1. Clinical findings and cerebrospinal characteristics of 22 patients with Acinetobacter meningitis 
Case Age Gender Leukocytes Neutrophils Lymphocytes  Glucose  Protein Trauma External Outcome 
   (cells/mm3) (%) (%) (mg/dL) (mg/dL)   shunt 
#1 38 F 1536 89 11 2 1258 N N Death
#2 45 F 20 3 12 44 191 N Y Death
#3 30 M 5 0 0 40 45 Y N Death
#4 59 M 410 100 0 17 352 N Y Death
#5 38 M 18 10 0 1 92 N Y Death
#6 21 M 69 10 84 45 41 N Y Death
#7 57 F 876 70 22 73 32 N N Survival
#8 53 F 540 100 0 1 134 N Y Death
#9 23 F 350 100 0 1 43 N Y Death
#10 39 M 35 85 13 55 33 Y Y Survival
#11 40 F 53 44 56 101 94 N Y Death
#12 78 M 15 3 97 1 119 N Y Death
#13 38 M 960 60 40 38 128 N Y Survival
#14 25 M 12800 96 4 1 590 Y N Survival
#15 46 M 150 42 54 43 37 Y Y Death
#16 56 M 683 79 19 2 161 N Y Death
#17 49 M 890 89 11 55 315 N Y Death
#18 27 F 19 68 27 54 32 N N Survival
#19 91 F 9300 98 2 13 722 N Y Death
#20 56 M 1700 100 0 5 176 N N Death
#21 64 F 1250 100 0 1 428 N Y Death
#22 2 F 2218 95 2 56 1844 N Y Survival
RESULTS
In this case study, we report 22 cases of meningitis caused by 
A. baumannii. The mean age of patients was 43.6 year (21 to 
91) and 54.5% were male. Cerebrospinal ﬂ uid culture grew 
A. baumannii within 60 days of admission, and the mean 
length of hospital stay was 18.2 days. Patients and cerebro-
spinal characteristics are described in Table 1. Two patients 
were excluded due to contamination/colonization.
All cases had previous neurosurgery procedures, in-
cluding elective surgery (27.3%), external shunt (54.5%), 
and emergency surgery due to trauma (18.1%).
Antibiotic susceptibility pattern of isolated A. bauman-
nii is described in Table 2. Susceptibility to imipenem and 
ampicillin/sulbactam was ascertained in 13 (59%) and 16 
(73%) of the isolates, respectively. The fatality rate among 
ANM patients was of 72.7%. None of the evaluated risk 
factors was signifi cantly associated to patient mortality. 
Out of 22 patients, only 17 (77.2%) received treatment, 
including two patients who received intrathecal therapy 
in addition to systemic antibiotics. The reason for abstain-
ing from antimicrobial treatment in four cases was death 
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Treatment of A. baumannii is an issue of concern, spe-
cifi cally because of the increasing prevalence of carbapen-
em resistance and colistin and polymyxin use. In our study, 
treatment with carbapenem would have failed in more 
than 40% of cases. The reason for the failure attributed to 
carbapenems is not clear. A. baumannii showed increased 
susceptibility to sulbactam. In our hospital, all strains were 
routinely tested using the diffusion disc assay for polymyx-
in susceptibility, but this method is not reliable. Sulbactam 
is an effective drug against Acinetobacter, as confi rmed by 
in vitro and in vivo studies, as well as by several clinical 
trials.10 However, physicians continue to avoid this drug, 
preferring colistin/polymyxin. Resistance to polymyxins is 
rare, even in a hospital with high incidence of carbapen-
em-resistant P. aeruginosa, although some cases have been 
published.11
before final culture results. Appropriate antibiotic ther-
apy was initially administered to 100% of the surviving 
patients, whereas only 69% (9/16) of patients who did 
not survive received it. There was no significant differ-
ence between survivors or therapies (OR = 5.15; IC = 
0.45-54.01). Ventricular shunts were removed from all pa-
tients with confi rmed meningitis.
DISCUSSION
The mortality rate observed in this study was high (73%). 
Mortality rates ranging from 30%-70% have been pre-
viously reported and are generally higher in developing 
countries.4,5,7,8 Studies assessing the mortality rate associ-
ated with meningitis have confi rmed higher mortality rates 
associated with Acinetobacter as compared to other Gram-
negative bacilli.4,9 
Table 2. Comparison of risk factors, antibiotic susceptibilities and outcomes of 22 patients with Acinetobacter 
meningitis according to their survival status
Variable Survived Died All
 (6 cases) (16 cases) (22 cases)
Gender (male) 2 (50.0%) 10 (62.5%) 12 (54.5%)
Age (Mean with Range) 39 [27-57] 45.5 [21-91] 43 [21-91]
Days of admission before infection (Mean with Range) 12 [3-32] 17 [3-60] 16 [3-60]
Total hospitalization (Mean with Range) 50 [9-115] 30.5 [10-96] 40 [9-115]
Trauma 1 (16.6%) 3 (18.7%) 4 (18.1%)
Elective surgery 2 (33.3%) 4 (25.0%) 6 (27.2%)
After shunt 3 (50.0%) 9 (56.3%) 12 (54.5%)
Previous antibiotic use 3 (50.0%) 14 (87.5%) 17 (77.2%)
Antibiotic sensibility      
Amikacin 3 (50%) 4 (25%) 7 (31.8%)
Gentamycin 3 (50%) 4 (25%) 7 (31.8%)
Tobramycin 3 (50%) 6 (37.5%) 9 (40.9%)
Ampicillin/Sulbactam 5 (83.3%) 11 (68.8%) 16 (72.7%)
Aztreonam 2 (33.3%) 0 (0%) 2 (9.1%)
Cefepime 3 (50%) 2 (12.5%) 5 (22.7%)
Ciprofloxacin 3 (50%) 3 (18.8%) 6 (27.3%)
Imipenem 5 (83.3%) 8 (50.0%) 13 (59.1%)
Meropenem 5 (83.3%) 7 (43.8%) 12 (54.5%)
Piperacillin/Tazobactam 3 (50%) 5 (31.3%) 8 (36.4%)
Treatment      
Intrathecal therapy 0 (0.0%) 2 (12.5%) 2 (9.9%)
Systemic antibiotic 4 (66.6%) 13 (81.2%) 17 (77.2%)
Appropriate therapy according to antimicrobial resistance* 4 (100.0%) 9 (69.2%) 13 (59.0%)
* The percentage was calculated for all patients using systemic antibiotics.
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Polymyxins penetrate the cerebrospinal ﬂ uid and pro-
duce sustained bactericidal concentrations. Intrathecal 
therapy further improves patient outcomes.12 Association 
of antibiotics have been suggested to improve patient out-
come, but the literature regarding this issue is scarce.7,13-15 
Rifampicin and aminoglycosides are drugs that can be used 
in association with polymyxins or carbapenems. 
Tigecycline is a therapeutic option; however, its effective-
ness for meningitis has not been studied yet. Wadi and Rub 
published an ANM case successfully treated with tigecycline.16 
Pharmacokinetic and pharmacodynamic data indicate that tige-
cycline blood concentrations seem to be suboptimal for exert-
ing maximal antibacterial activity at this compartment. Aggres-
sive treatment of A. baumannii meningitis using a multidrug 
regimen, including intrathecal therapy, appears to be indicated. 
In our study, only two patients were treated with intrathecal 
therapy. This could be one explanation for the high mortality 
rate. In a recent review, intrathecal plus systemic therapy was 
recommended for treatment of ANM patients.17
Risk factors are important in predicting the outcomes 
of ANM patients. A case-control study showed a higher 
incidence of hydrocephaly in patients with Acinetobacter.8 
Although not technically defi ned as a risk factor, previous 
colonization with Acinetobacter is thought to increase risk of 
developing ANM.18-20 In our institution, A. baumannii is the 
most common cause of ventilator-associated pneumonia 
and is commonly isolated from several sites in the patient.
In conclusion, Acinetobacter meningitis is a hazardous 
infection in neurosurgery units. Actions aiming at reducing 
post-surgery or shunt infection must be evaluated routinely. 
The high mortality rate observed in our study suggests the 
need for treatment with active agents against Acinetobacter, 
especially in settings where this microorganism is endemic. 
It is also recommended the addition of intrathecal therapy 
after identifi cation of the bacterium. Prospective trials with 
intrathecal and intravenous colistin could help defi ning an 
appropriate therapy for A. baumannii meningitis. 
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